Form 4: Sage Therapeutics Director Jeffrey Jonas Awarded Stock Options

Director Jeffrey Jonas of Sage Therapeutics, Inc. was granted stock options under the company's 2024 Equity Incentive Plan.

Summary

• Jeffrey Jonas, a director at Sage Therapeutics, Inc., was granted stock options on June 10, 2024.
• The options, totaling 12,500 shares, were awarded under the company's 2024 Equity Incentive Plan as part of the Non-Employee Director Compensation Program.
• The exercise price of the options is $10.90 per share.
• The options will vest fully on the earlier of June 10, 2025, or the day before the 2025 Annual Meeting of Sage's stockholders, contingent upon continued service as a director.
• Brandon Marsh, acting as Attorney-in-Fact, signed the Form 4 on behalf of Jeffrey Jonas.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholder value. There are no indications of negative performance or concerning issues.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The director's continued service is incentivized through the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotechnology industry.
• Companies like Biogen and Vertex Pharmaceuticals also utilize stock options as part of their director compensation, but the specific terms and amounts depend on factors such as company size, performance, and individual contributions.
• The vesting schedule and exercise price of these options are generally in line with industry practices for incentivizing long-term commitment and value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates